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CC BY-NC-ND license (http://creativBackground: Sickle cell disease (SCD) is a genetic disorder that results in deformity of red
blood cells. Renal dysfunction affects 5e18% of patients with SCD. To date, few studies have
described urinary levels of transforming growth factor b-1 (TGF-b1), which is a marker of
fibrosis, as a biomarker in identifying patients at risk of developing renal disease in SCD.
The aim of this study is to determine prevalence of sickle cell nephropathy in Egyptian SCD pa-
tients. We aimed also to evaluate the association of urinary TGF-b1 with other conventional
biomarkers of renal damage in SCD patients to identify a novel renal biomarker for early diag-
nosis of sickle nephropathy.
Methods: We examined 40 SCD patients, 21 with sickle cell anemia, 16 sickle thalassemia, and
three with sickle trait. We compared them to 20 control children with matched age and sex.
The study was held in the time period between May 2013 and December 2013 in the Hematol-
ogy Clinic, New Cairo University Children Hospital, Cairo, Egypt.
Results: Urinary excretion of TGF-b1 was 7.07  1.91 ng/mL in SCD patients versus
2.23  0.76 ng/mL in control children (p < 0.001). SCD patients had elevated estimated
glomerular filtration rate (177.44  35.6 mL/min/1.73 m2), denoting a state of glomerular hy-
perfiltration. 47.5% of SCD patients had microalbuminuria. Urinary TGF-b1 correlated posi-
tively with microalbuminuria and estimated glomerular filtration rate (p Z 0.001 and
p Z 0.018, respectively).ed Abdel-Moneam Street, off Rayel Street, Helwan, Cairo, Egypt.
oo.com (E.E. Ghobrial).
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Urinary TGF-b1 in sickle nephropathy 175Conclusion: We concluded that urinary TGF-b1 may serve as a marker of early renal injury in
SCD.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Sickle-cell disease (SCD) is a multisystem disease, associ-
ated with episodes of acute illness and progressive organ
damage and it is one of the most common severe mono-
genic disorders worldwide.1 Sickle nephropathy (SN) is one
of the most serious complications of SCD. It is characterized
by insufficient angiogenesis due to the imbalance between
proangiogenic and antiangiogenic process. As the disease
progresses, end-stage renal disease develops.2
Patients with SCD must be considered at risk for chronic
kidney disease (CKD), and they should have regular (at least
once per year) measurements of the urinary albumin to
creatinine ratio for early detection in children. Prolonged
hyperfiltration results in renal damage and the develop-
ment of proteinuria. The hyperfiltration and proteinuria
cause glomerulosclerosis and reduction in kidney function.3
Proteinuria begins as microalbuminuria (MA) and pro-
gresses to overt proteinuria as the kidney sustains further
damage resulting from SCD. MA is one of the earliest
markers of kidney damage and has been found to be
directly related to age and inversely related to hemoglobin
levels among SCD children.4
Angiotensin II also stimulates growth factors, including
transforming growth factor b-1 (TGF-b1), a potent fibro-
genic growth factor that may play a significant role in
pathogenesis of SN.5 It is a peptide of low molecular weight
and has pleiotropic action. In the kidneys, it stimulates
fibrogenesis through enhanced production of extracellular
matrix proteins and nephron loss by various mechanisms,
such as apoptosis of endothelial cells and podocytes.6
Whether the urinary levels of TGF-b1 has a diagnostic
significance in the early prediction of SN in children with
SCD is still to be determined.7
The aim of this study is to determine the prevalence of
SN in Egyptian SCD patients and to determine the risk fac-
tors for SN. We aim also to evaluate the association of
urinary TGF-b1 with other conventional biomarkers of renal
damage in SCD patients [MA, serum creatinine, and esti-
mated glomerular filtration rate (eGFR)] in order to identify
a novel renal biomarker for early diagnosis of SN.
2. Methods
This is a cross-sectional study conducted on a cohort of 40
SCD patients who attended the Hematology Clinic, New
Cairo University Children Hospital (NCUCH), Cairo, Egypt
during their regular health maintenance visits, between
May 2013 and December 2013.
SCD patients aged 2e18 years diagnosed by hemoglobin
electrophoresis were included in the study. Patients withclinical or laboratory findings of previous or current renal
disease with any organ failure or with diseases that may
cause elevation of urinary level of TGF-b1 (e.g., cardiac
diseases, neoplasm) were excluded from the study.
Twenty-one patients were diagnosed as sickle cell ane-
mia (52.5%), 16 as sickle-thalassemia (40%), and three as
sickle cell trait (7.5%) formed the patient groups. Eleven
were boys and the other 29 were girls.
Thirty-eight of the 40 patients were treated with hy-
droxyurea, while six patients were on iron chelating
treatment.
Twenty children with matched age and sex were selected
from those who attended the pediatric general outpatient
clinics at NCUCH; 14 were boys and six were girls. They were
enrolled as controls for urinary TGF-b1. They were sub-
jected to the same exclusion criteria as the patients.
Informed consent was taken from parents of all children
participating in the study.
All patientswere subjected to a full history [including age,
sex, consanguinity, duration of illness, blood transfusion,
vaso-occlusive crises, frequency of hospital admission, his-
tory of infections, splenic status, urinary symptoms (poly-
uria, hematuria, etc.), drug therapy (chelation and
hydroxyurea) and complications] and physical examination
including body weight and its percentile, standing height and
its percentile, body mass index (BMI), vital signs [blood
pressure (BP) and its percentile, where BP levels < 90th
percentile are considered normal, levels between 90the95th
percentiles are considered prehypertension, and
levels > 95th percentiles are considered hypertension],
pallor, jaundice, and abdominal examination to detect he-
patomegaly and splenomegaly. Medical records were
reviewed for demographic data and clinical events.
The following laboratory investigations were done:
complete blood count [using Sysmex KX-21N]; liver function
tests (alanine aminotransferase, aspartate amino trans-
ferase and serum albumin), kidney function tests(blood
urea nitrogen and serum creatinine) and iron indices (serum
iron and serum ferritin) [using Beckman Coulter CX9pro];
hemoglobin electrophoresis [using Hyrys_Sebia]; urinalysis
(urine samples were centrifuged; dipsticks were used to
detect sugar and albumin, then urine samples were
microscopically examined) and 24 hours urinary proteins.
The results of hepatitis B surface antigen and hepatitis C
antibodies using enzyme-linked immunosorbent assays for
all patients were recorded.
eGFR was calculated for all patients using the Schwartz
formula.8
Urinary TGF-b1 was measured for all patients. Normal
range is 2e12 ng/mL. The determination of urinary TGF-b1
was accomplished by using a commercially available kit,
Abcam’s TGF-b1 Human ELISA kit, in a fresh urine sample
176 E.E. Ghobrial et algiven by every patient. The kit is designed for the quanti-
tative measurement of human TGF-b1 in serum, cell culture
supernatants and urine.9
2.1. Statistical analysis
The SPSS (version 19.0; SPSS Inc., Chicago, IL, USA) and
Microsoft Excel programs were used to tabulate the results
and represent them graphically. Quantitative variables
were expressed as mean and standard error. Qualitative
variables were expressed as count and percentage. The
one-way analysis of variance was used to test the differ-
ences between groups. The Duncan multiple comparison
test was used to test the significant differences between
each pair of groups. The Chi-square test was used to
compare the distributions between groups. The Pearson
correlation coefficient test used to test the significant
correlations between the quantitative parameters within
each group. A p value < 0.05 is considered significant.103. Results
The 40 patients included 29 girls (72.5 %) and 11 boys
(27.5%). Table 1 shows comparison between the three pa-
tient groups and control group regarding mean age, sex,
and the disease duration of patient groups.
The mean age of patients at time of first presentation
was 2.6  2.53 years. All patients were diagnosed before
the age of 10 years. All patients were negative for hepatitis
B and C viruses.
The 20 controls were six girls (30%) and 14 boys (70%).
Their mean age at the time of the study was 8.12  4.16
years.
There were no statistically significant differences with
regard to mean age and sex between the patient groups and
the control group.Table 1 Basic demographic data of all participants.
Sickle cell (n Z 21) Sickle trait
Age (y) Mean  SE 10.9  5.4 3.83  1
<5 y
17 (28.3)
4 (19) 2 (66.67)
5e10 y
21 (35)
6 (28.5) 1 (33.33)
>10 y
22 (36.6)
11 (52.5) 0
Sex Male
25 (41.66)
3 (14.3) 0
Female
35 (58.33)
18 (85.7) 3 (100)
Disease
duration
<5 y
19 (47.5)
9 (43) 3 (100)
5e10 y
11 (27.5)
4 (19) 0
>10 y
10 (25)
8 (38) 0
Data are presented as n (%) unless otherwise indicated.
SE Z standard error.Table 2 shows comparison between three patient groups
and control group for mean weight, mean height, and mean
BMI, and indicates that there were no statistically signifi-
cant differences in these.
There was a statistically significant difference between
the different study groups regarding the systolic BP (SBP)
and diastolic BP; however, the highest mean blood pressure
was found in the sickle cell group, followed by sickle thal-
assemia group, and then the control and the sickle trait
groups were nearly equal (p < 0.001). Although SBP was
normal (< 90th percentile) in all study groups, 13 of 40
patients (32.5%) presented with diastolic prehypertension
(90the95th percentile), and four of 40 patients (10%) had
diastolic hypertension.
Patients of the sickle cell group showed significantly
higher level of adult hemoglobin (Hb) and sickle Hb than
that in other groups of patients (p Z 0.036 and p Z 0.001
respectively), while patients of sickle thalassemia group
showed significantly higher level of fetal Hb than other
groups of patients (pZ 0.001). Our study revealed that 95%
of SCD patients participating in our study were on hy-
droxyurea treatment, 20% of whom had never received
blood transfusion.
Table 3 shows a comparison between the four groups for
complete blood count. The sickle trait group showed
significantly higher levels of Hb, hematocrit, and red blood
corpuscles, followed by the sickle cell anemia group then
the sickle thalassemia group (pZ 0.001 for all). Also mean
corpuscular Hb and mean corpuscular Hb concentration
showed significantly higher levels in the sickle trait group
than other groups (pZ 0.007 and pZ 0.001, respectively).
Red cell distribution width was significantly higher in the
sickle thalassemia group, followed by the sickle cell anemia
and then the sickle trait group (p Z 0.001).
Serum albumin and BUN were significantly higher in the
sickle trait group than in other patient groups (p Z 0.007
and p Z 0.001, respectively), while creatinine was(n Z 3) Sickle thalassemia (n Z 16) Control (n Z 20)
7.8  4.6 8.12  4.16
6 (37.5) 5 (25)
4 (25) 10 (50)
6 (37.5) 5 (25)
8 (50) 14 (70)
8 (50) 6 (30)
7 (43.75)
7 (43.75)
2 (12.5)
Table 2 Anthropometric measures.
Sickle cell Sickle trait Sickle thalassemia Control F p
Weight (kg) 34.07  4 15.33  1.3 26.06  3.4 26.97  2.9 1.892 0.141
Height (cm) 131.4  5.5 102.3  5.3 119.25  7 124.7  4.5 1.646 0.189
BMI (kg/m2) 18.41  0.8 14.62  0.3 16.45  0.7 16.28  0.7 2.045 0.118
Data are presented as mean  standard error.
BMI Z body mass index.
Table 3 Complete blood and reticulocyte counts.
Sickle cell (n Z 21) Sickle trait (n Z 3) S. thalassemia (n Z 16) Control (n Z 20) F p
Rtx (%) 4.43  0.51 4.9  0.49 6  0.82 * 1.493 0.238
Hb (g/dL) 9.10  0.42 11  0.51 8.88  0.37 11.72  0.21 15.210 0.001
RBCs 1012/L 3.25  0.14 3.71  0.23 3.39  0.16 4.47  0.04 20.579 0.001
Hct (%) 26.36  1.34 32.4  1.77 26.06  0.87 36.72  0.62 24.273 0.001
MCV (fl) 81.87  1.63 88.46  1.86 82.11  4.7 81.65  1.31 0.328 0.805
MCH (pg) 28.54  0.64 31.73  0.84 26.48  0.89 26.66  0.43 4.503 0.007
MCHC (g %) 34.29  0.29 35  1 33.96  0.57 31.87  0.44 7.244 0.001
RDW (%) 18.61  0.79 14.7  0.95 18.85  0.87 14.83  0.35 8.064 0.001
PLT 109/L 368.4  24.93 564.3  5.54 245.6  30.02 350.7  21.84 8.860 0.001
TLC 109/L 9.16  0.82 8.93  0.4 8.4  1.09 9.07  0.59 0.157 0.925
Data are presented as mean  standard error.
Hb Z hemoglobin; Hct Z hematocrit; MCH Z mean corpuscular hemoglobin; MCHC Z mean corpuscular hemoglobin concentration;
MCV Z mean corpuscular volume; Plt Z platelet count; RBCs Z red blood corpuscles; RDW Z red cell distribution width;
Rtx Z reticulocyte count; SE Z standard error; TLC Z total leukocyte count.
* Reticulocytic counts were not done for control group.
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(p Z 0.032), taking in consideration that the highest
creatinine level was 0.7, which is considered normal for
age. The levels of BUN and creatinine were significantly
lower in the overall SCD patients (BUN 8.5  1.1 mg/dl,
creatinine 0.4  0.1 mg/dl), compared with the values in
controls (BUN 12.1  4.17 mg/dl, creatinine 0.5  0 mg/dl).
Regarding urine analysis, red blood corpuscles in urine were
significantly higher in the sickle thalassemia group
(p Z 0.001).
Table 4 shows a comparison between the four groups for
24 hours urinary proteins, MA, eGFR, and urinary TGF-b1.Table 4 Twenty-four-hour urinary protein, MA, eGFR, and urin
Sickle cell
(n Z 21)
Sickle trait
(n Z 3)
S
(
24-h urinary proteins
(mg/24 h)
174.4  13.6 87.66  3.9 1
MA (n Z 23) 12 (57.1) 0 7
eGFR
mL/min/1.73 m2
187.28  5.3 170.32  7.5 1
TGF-b1 ng/mL 8.03  0.4 6.35  0.3 5
Data are presented as n (%) or mean  standard error.
eGFR Z estimated glomerular filtration rate; MA Z microalbuminuria
* Significant different at p < 0.05 between groups.
y Highly significant different at p < 0.01 between groups.MA was found in 19 of 40 SCD patients (47.5%) [12 had sickle
cell anemia (57%) and 7 had sickle thalassemia (44%)], while
none of the sickle trait patients presented with MA. By
contrast, MA was present in four of the 20 control children
(20%).
The mean value of eGFR was 177.44  35.6 mL/min/
1.73 m2 and the mean value of urinary TGF-b1 was
7.07  1.91 ng/mL. The highest level of eGFR and urinary
TGF-b1 was found in the sickle cell anemia group followed
by the sickle trait group then the sickle thalassemia group
and then the control group which had the lowest values
(p Z 0.007 for eGFR and p Z 0.001 for TGF-b1).ary TGF-b1.
ickle thalassemia
n Z 16)
Control
(n Z 20)
F p
64.68  11.6 136.17  8.9 3.955* 0.013
(43.7) 4 (20)
65.85  11.6 147.29  7.7 4.514y 0.007
.96  0.3 2.23  0.1 58.437y 0.001
; TGF-b1 Z transforming growth factor b-1.
178 E.E. Ghobrial et alThere was a significant positive correlation between
eGFR and BMI in SCD patients (r Z 0.34, p Z 0.027), and
eGFR had a significant negative correlation with serum
creatinine level (r Z 0.361, p Z 0.022).
Table 5 shows correlation of TGF-b1 with age, BMI, Hb,
fetal Hb, sickle Hb, BUN, serum creatinine, MA, and eGFR in
the different patient groups. Urinary TGF-b1 tends to be
higher at younger age. Urinary TGF-b1 had a strongly pos-
itive significant correlation with eGFR and MA. This corre-
lation was found in the total of all SCD patients (r Z 0.50
and r Z 0.21; p Z 0.001 and p Z 0.018, respectively).
However, TGF-b1 was significantly negatively correlated to
Hb (r Z 0.52, p Z 0.031) and serum creatinine level
(r Z 0.45, p Z 0.018) in the same two groups. A statis-
tically significant negative correlation was found between
urinary TGF-b1 and fetal Hb (r Z 0.41, p Z 0.043) only in
patients with sickle cell anemia but not in the other groups.4. Discussion
Standard renal function tests such as serum creatinine and
eGFR become abnormal only when renal damage has
become extensive and irreversible. Therefore, early
markers are needed for early diagnosis of SN before kidney
damage becomes irreversible, so that therapeutic in-
terventions are effective at preventing progression of renal
damage.11
Currently, MA and creatinine are the only markers of
advanced renal injury. To find noninvasive urinary markers
of early renal damage in SCD, we examined urinary levels of
TGF-b1, which is a known profibrogenic cytokine that plays
an important role in the progression of CKD. TGF-b1 has
been shown to directly induce both increased synthesis and
reduced degradation of matrix proteins, leading to a net
accumulation of pathological matrix, thereby playing a role
in the fibrotic process.12
The female predominance in the patient groups is
explained by most older male adolescents being referred to
the adult hematology clinic. The male predominance in the
control group is explained by the control sample beingTable 5 Correlations of urinary transforming growth factor b-1
Urinary TGF-b1
All SCD patients (nZ 40) SCA (n Z 21)
r p Sig r p Sig
Age 0.160 0.791 NS 0.172 0.456 NS
BMI 0.206 0.203 NS 0.125 0.590 NS
Hb 0.783 0.045 S 0.526 0.031 S
Hb F 0.110 0.501 NS 0.413 0.043 S
Hb S 0.109 0.502 NS 0.413 0.063 NS
BUN 0.076 0.643 NS 0.032 0.889 NS
Creat 0.45 0.003 S 0.510 0.018 S
MA 0.50 0.001 S 0.650 0.001 S
eGFR 0.213 0.018 S 0.042 0.030 S
BMI Z body mass index; BUN Z blood urea nitrogen; Creat
HbZ hemoglobin; HbFZ fetal hemoglobin; HbSZ sickle hemoglobintaken randomly from those who attended the general pe-
diatric outpatient clinics, NCUCH.
Our study revealed that there was no statistically sig-
nificant difference in weight, height, and BMI between
different groups of patients and controls. These results are
consistent with that of Mohtat et al,7 who did not find a
significant difference in mean BMI between SCD patients
and controls, but this was not consistent with Barden
et al,13 who concluded that children with SCD had impaired
growth, delayed puberty and poor nutritional status.
Interestingly, our study identified normal SBP in all pa-
tients but elevated diastolic BP in 17 of 40 SCD patients
(42.5%; diastolic hypertension in 10% and prehypertension
in 32.5%). Aygun et al14 identified no hypertensive patients
despite abnormal calculated and measured GFR. In addi-
tion, in a Saudi Arabian cohort of children with SCD aged
1e16 years, BP measurements were within normal range.15
However, in a study performed by Bodas et al16 on SCD
patients aged 3e18 years, 16.6% had elevated BP (hyper-
tension in 8.3%, prehypertension in 8.3%).
The levels of BUN and creatinine were significantly lower
in the overall SCD patients, compared with the values in
controls, but both values were still within the normal range
(p Z 0.001 and p Z 0.032 respectively). Our results also
matched those of Thompson et al,17 who found that serum
creatinine levels were lower in patients with sickle cell
disease compared with controls.
The low level of serum creatinine may be explained by
the likelihood of tubular dysfunction in SCD patients, as
well as an increased tubular secretion of creatinine.18 In
addition, diet influences the BUN and creatinine level.19
Since diet and muscle mass were not controlled during
our study, further investigations are necessary to study the
possible contribution of these variables on the level of
biochemical parameters.
In our study, the overall prevalence of MA in patients
with SCD was 47%; the majority of them had sickle cell
anemia (63.2%) and the rest had sickle thalassemia (36.8%),
while no of sickle trait patients had MA.
A lower percentage was reported by McBurney et al,4
who found MA in 19% of patients with SCD. Also, Datta(TGF-b1).
correlations
S trait (n Z 3) S thalassemia (n Z 16)
r p Sign. r p Sig
0.17 0.891 NS 0.139 0.608 NS
0.498 0.668 NS 0.086 0.750 NS
0.68 0.523 NS 0.114 0.673 NS
0.6 0.521 NS 0.123 0.649 S
0.57 0.608 NS 0.064 0.813 NS
0.071 0.955 NS 0.395 0.130 NS
0.071 0.955 NS 0.109 0.689 NS
0.974 0.147 NS 0.257 0.336 NS
0.20 0.867 NS 0.075 0.784 NS
Z creatinine; eGFR Z estimated glomerular filtration rate;
; MAZ micro-albuminuria; NSZ non-significant; SZ significant.
Urinary TGF-b1 in sickle nephropathy 179et al20 reported a 19.2% prevalence of MA among Indian
children with SCD. Similarly Alvarez et al21 recorded a
prevalence of 16.8% among SS children and 18% amongst the
SC group. Imuetinyan et al15 found MA in 20.3%. The slight
difference between the overall prevalence of MA and that
in our study is probably due to the increased number of
older SCD patients in our study (42.5% aged 10e18 years),
as the prevalence of MA increases with increasing age as
proved by a previous study done by King et al22 on Jamaican
children with SCD.
Our results demonstrate the presence of higher eGFR in
SCD patients than in controls denoting hyperfiltration
(p Z 0.007). Similarly, in a study by Bodas et al,16 on a
cohort of SCD patients with mean age 12  3 years, 73% of
patients had elevated eGFR with mean value
140  34.9 mL/min/1.73 m2. Aygun et al14 studied 85
children with SCD with mean age 9.5  4.8 years, 77 with
sickle cell anemia and eight with sickleethalassemia, and
revealed that 76% of patients had elevated eGFR with mean
value 154  37 mL/min/1.73 m2. Also, Thompson et al17
determined that eGFR was 19% greater in SCD patients
than controls.
In contrast to our findings, a cross-sectional study by Yee
et al23 reported an 11.6% prevalence of eGFR < 90 mL/min/
1.73 m2 in their patients (mean age 11.4  4.5 years),
supporting the idea that CKD may be more common in the
pediatric population.
In this study we found a significantly positive correlation
between eGFR and BMI in SCD patients (r Z 0.34,
p Z 0.027). Similarly, Lo et al24 reported a significant
interaction between eGFR and BMI (p < 0.001). This cor-
relation may be explained by the fact that the Schwartz
formula that was used to estimate the GFR depends on the
height of the patients as a variable in the equation.8
We found a significantly negative correlation between
eGFR and hemoglobin F only in the group of sickle cell
anemia patients (Hb SS; r Z 0.139, p Z 0.049), which is
consistent with results of Haymann el al25 in a study on
adult patients with homozygous SS hemoglobinopathy. They
found that hyperfiltration status was significantly associ-
ated with lower hemoglobin and lower hemoglobin F.
In our study, urinary excretion of TGF-b1 was
7.07  1.91 ng/mL in SCD patients and 2.23  0.76 ng/mL in
the control group (p Z 0.001). The highest level was in
sickle cell anemia patients, followed by sickle trait and
then sickle thalassemia patients. Similarly Mohtat et al,7 in
a study on 51 SCD patients aged 2e21 years (42 HbSS, 8
HbSC, and 1 HbSD), found that urinary TGF-b1 was signifi-
cantly higher in patients than in controls.
In this study, TGF-b1 tended to be higher at younger
ages. Okamoto et al26 also reported that the serum TGF-b1
level in children (age 0e14 years) was significantly higher
than that of patients older than 15 years.
In addition, we observed that urinary TGF-b1 had a
significantly negative correlation with Hb and fetal Hb
levels in patients with sickle cell anemia (Hb SS;
r Z 0.52 and r Z 0.41; p Z 0.031 and p Z 0.043,
respectively). This result is consistent with that of Mohtat
et al,7 who found that patient with Hb < 9 g/dL had
higher urinary TGF-b1 than patients with milder anemia.
This may be explained by the fact that lower Hb levels
(anemia) lead to tissue hypoxia which in turn worsens therenal condition on top of the renal pathology caused by
the sickle cell disease itself.
Furthermore, we detected a significantly negative cor-
relation between urinary TGF-b1 and serum creatinine
(r Z 45, p Z 0.018), which may be explained by the fact
that glomerular hyperfiltration contributed to lowering the
levels of serum creatinine in SCD patients.17
Nevertheless, we found a strong positive correlation
between urinary TGF-b1 and urinary proteins and eGFR in
all groups of SCD patients studied (r Z 0.50 and r Z 0.21;
p Z 0.001 and p Z 0.018, respectively) which are consid-
ered to be markers for the degree and severity of SN. This is
in agreement with Mohtat et al,7 who concluded that uri-
nary TGF-b1 was a marker of early renal injury in SCD more
than MA.
One major limitation of this study was small number of
the study population.
In conclusion, urinary TGF-b1 could be used as a simple
and sensitive test in the diagnosis of early renal dysfunction
in patients with SCD as it correlated positively with eGFR
and MA, which are considered to be the earliest markers of
SN. Close follow up of SCD patients is important to identify
patients at risk of developing SN. Also, it is of a great
importance to take into consideration that lower hemo-
globin levels are associated with higher risk of developing
renal disease.Conflicts of interest
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